At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 133 enrolled
Drug / intervention
fingolimoddrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Long-term Follow up of Patients With Relapsing-remitting Multiple Sclerosis Enrolled in the Multicenter, Single-arm, Open-label Biobank Study (CFTY720DDE01), to Investigate Changes in Biomarkers After 48 Months of Treatment With 0.5 mg Fingolimod (FTY720)
In Brief
A Phase 4 clinical trial evaluating fingolimod for Relapsing-remitting Multiple Sclerosis. Completed, enrolled 133 participants across 26 sites.
Detailed Summary
The purpose of this single visit extension study is to explore immune status in RRMS patients treated for at least 48 months with fingolimod. Long-term changes in T cell counts will be compared to short-term changes in immune status (baseline to month 6) after treatment start with fingolimod as assessed in the original Biobank study (CFTY720DDE01).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsing-remitting Multiple Sclerosis
CountriesGermany
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartMay 2016
Primary CompletionNov 2016
TodayJul 2026
First PostedMar 25, 2016
Enrollment StartMay 12, 2016
Primary CompletionNov 14, 2016
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 10.3 years ago
Interventions
fingolimoddrug